CAMBRIDGE, Mass., March 26 /PRNewswire/ -- Genstruct Inc., a biotechnology company translating the complexity of human biology to develop new successful therapeutics, today announced the appointment of Christian Reich, M.D., Ph.D. to vice president of Scientific Research. In this position, Dr. Reich will lead Genstruct’s internal biology research teams as well as efforts in translational medicine and clinical research in partnership with its large pharmaceutical partners, which include GSK and Pfizer.
“Systems biology and translational medicine are making a real impact in drug development, and leading pharmaceutical and biotechnology companies are turning to us to develop a detailed understanding of molecular mechanisms for their drugs. To successfully develop new drugs in today’s environment it is essential to understand the complexity of human biology and to translate this intelligence into drug development. As a result of our successes, our partnerships have grown and our current relationships continue to expand,” explained Keith O. Elliston, Ph.D., president and CEO of Genstruct. “Christian brings a unique blend of expansive experience in medicine, biology and technology. As both a practicing physician and a life science executive, Christian will be invaluable as Genstruct embarks on the next phase of our scientific growth.”
Dr. Reich has more than 15 years of experience in life science research and medicine. He was a practicing physician in Berlin and Ulm, Germany before moving to the European Bioinformatics Institute to work on the Human Genome Project. Dr. Reich joined Millennium Pharmaceuticals in 1998, where he was responsible for a number of key programs, including Millennium’s pathways initiative. He was also the global head of Clinical Informatics for Millennium, where he was responsible for strategy and operations in the areas of drug development, safety, clinical research and clinical trial management. Dr. Reich received his bachelor’s degree in preclinical training from Humboldt University in Berlin and holds an M.D. and Ph.D. from the Medical University of Lubeck where he focused research on T-cell activation and regulation.
About Genstruct
Founded in 2002, Genstruct is a biotechnology company focused on elucidating the complexity of biology for the development of successful therapeutics. By modeling of the components within the whole biological system, Genstruct delivers a deep molecular understanding of diseases and drug action, as well as mechanistic biomarkers to accelerate drug discovery and development programs. Genstruct engages in internal discovery and external development partnerships with top tier pharmaceutical companies, which apply systems biology in the areas of oncology, metabolic disorders, cardiovascular diseases and inflammation. The privately held company is based in Cambridge, Mass. For more information, please visit www.genstruct.com.
Genstruct and the Genstruct logo are registered trademarks and Molecular Epistemics, Knowledge Assembly, and Epistemics Engine are trademarks of Genstruct, Inc. All other trademarks or registered trademarks are properties of their respective owners.
Karen Higgins A & E Communications for Genstruct (610) 831-5723 khiggins@aandecomm.com
Genstruct Inc.
CONTACT: Karen Higgins, +1-610-831-5723, khiggins@aandecomm.com, of A & ECommunications for Genstruct
Web site: http://www.genstruct.com/
